NASDAQ:AXGN AxoGen Q2 2026 Earnings Report $39.48 -0.37 (-0.93%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$39.74 +0.26 (+0.66%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast AxoGen EPS ResultsActual EPSN/AConsensus EPS $0.09Beat/MissN/AOne Year Ago EPSN/AAxoGen Revenue ResultsActual RevenueN/AExpected Revenue$67.10 millionBeat/MissN/AYoY Revenue GrowthN/AAxoGen Announcement DetailsQuarterQ2 2026Date7/29/2026TimeBefore Market OpensConference Call DateWednesday, July 29, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile AxoGen Earnings HeadlinesAxoGen (NASDAQ:AXGN) Lowered to Hold Rating by Wall Street ZenJuly 18 at 1:19 AM | americanbankingnews.comAxogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026July 15, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.July 21 at 1:00 AM | Paradigm Press (Ad)AxoGen (NASDAQ:AXGN) Shares Down 6.7% - Here's WhyJuly 12, 2026 | americanbankingnews.comBrokerages Set AxoGen, Inc. (NASDAQ:AXGN) PT at $46.50July 10, 2026 | americanbankingnews.comAxoGen, stock of the day, offers entry after bullish reboundJune 5, 2026 | msn.comSee More AxoGen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AxoGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AxoGen and other key companies, straight to your email. Email Address About AxoGenAxoGen (NASDAQ:AXGN) is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts. The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue. These proprietary platforms are supported by a direct sales force in the United States and strategic distributor partnerships in international markets. AxoGen markets its technologies across North America, Europe, Australia and parts of Latin America, collaborating with surgeons in specialties such as hand, orthopedics, plastic and reconstructive surgery. The company leverages clinical training programs, peer-reviewed research and reimbursement support services to drive adoption of its nerve repair solutions. As it advances its product pipeline, AxoGen continues to seek regulatory clearances and expand its global footprint in the evolving field of peripheral nerve repair.View AxoGen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
